A transcendental experience: UNM clinical trial uses synthetic psilocybin to study end-of-life acceptance and anxiety

UNM is preparing to join a double-blind clinical trial exploring how psychedelics can help people with terminal or life-changing diagnoses. The study will use a synthetic form of psilocybin and pair two guided, therapist-supported sessions with participants during roughly three hours in a controlled setting. Researchers expect psilocybin to help patients relax mentally and shift their perspective, easing deep anxieties and, for some people, producing more “transcendental” experiences tied to acceptance about illness. The trial is designed around patients who may be medically fragile, so investigators selected a synthetic version to shorten effects compared with longer-lasting natural psilocybin trips. The article links the trial to growing medical interest in psychedelic therapies and to New Mexico’s evolving psilocybin framework for medicinal use. UNM plans to start the study in September with 10 participants, while emphasizing professional monitoring and guided support for difficult moments rather than framing them as “bad trips.”